Infarmed medicines authority has ordered the immediate suspension of sale of anti-anxiety medication Lorazepam Labesfal, marketed by Generis, due to a “problem with the dosage of a lote”. In a communiqué issued today, Generis has proceed in the voluntary collection of lote nº 21032, valid until January 2023. Says Infarmed, anyone using medication from this lote should not stop treatment, but “as soon as possible contact their doctor to substitute” with another lote, or an alternative medication.
Infarmed orders suspension of sale of ‘defective anti-anxiety’ meds
